MX2021001604A - Tratamiento del cáncer con un anticuerpo. - Google Patents
Tratamiento del cáncer con un anticuerpo.Info
- Publication number
- MX2021001604A MX2021001604A MX2021001604A MX2021001604A MX2021001604A MX 2021001604 A MX2021001604 A MX 2021001604A MX 2021001604 A MX2021001604 A MX 2021001604A MX 2021001604 A MX2021001604 A MX 2021001604A MX 2021001604 A MX2021001604 A MX 2021001604A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- cancer treatment
- cancer
- treatment
- kits
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813137.5A GB201813137D0 (en) | 2018-08-10 | 2018-08-10 | Cancer treatment with an antibody |
| PCT/EP2019/071627 WO2020030827A1 (en) | 2018-08-10 | 2019-08-12 | Cancer treatment with an antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001604A true MX2021001604A (es) | 2021-04-19 |
Family
ID=63667034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001604A MX2021001604A (es) | 2018-08-10 | 2019-08-12 | Tratamiento del cáncer con un anticuerpo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11858982B2 (enExample) |
| EP (1) | EP3833404A1 (enExample) |
| JP (2) | JP7428696B2 (enExample) |
| KR (1) | KR20210088523A (enExample) |
| CN (1) | CN112770786B (enExample) |
| AU (1) | AU2019319092B2 (enExample) |
| BR (1) | BR112021002435A2 (enExample) |
| GB (1) | GB201813137D0 (enExample) |
| IL (1) | IL280421B2 (enExample) |
| MX (1) | MX2021001604A (enExample) |
| TW (1) | TW202014437A (enExample) |
| WO (1) | WO2020030827A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250025553A1 (en) | 2021-11-18 | 2025-01-23 | Medannex Ltd. | Combination therapy for cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2219299A1 (en) | 1997-10-24 | 1999-04-24 | Elias Georges | P-40, a new member of the multidrug resistance gene family |
| US20040219572A1 (en) | 2002-12-17 | 2004-11-04 | Jie Chen | Specific markers for pancreatic cancer |
| EP1670510A1 (en) | 2003-09-24 | 2006-06-21 | Peter Krammer | Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
| JP5139058B2 (ja) | 2004-06-02 | 2013-02-06 | シドニー キンメル キャンサー センター | 新形成または新生脈管構造の検出、画像化および処置のための血管標的 |
| CN100571785C (zh) * | 2006-09-06 | 2009-12-23 | 中国医学科学院北京协和医院 | Annexin A3与癌症的铂类化疗药物耐药性的相关性 |
| GB0822011D0 (en) | 2008-12-02 | 2009-01-07 | Queen Mary & Westfield College | Treatment |
| EP2580241B1 (en) * | 2010-06-09 | 2020-11-04 | Queen Mary & Westfield College, University of London | Annexin 1 antibody |
| CN102898527B (zh) | 2011-07-25 | 2016-12-21 | 三星电子株式会社 | 融合蛋白、药物组合物及预防或治疗癌症的方法 |
| GB201121564D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Use of antibody |
| KR20150029457A (ko) | 2013-09-10 | 2015-03-18 | 삼성전자주식회사 | 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도 |
| US20160291025A1 (en) | 2013-09-18 | 2016-10-06 | Adelaide Research & Innovation Pty Ltd | Autoantibody biomarkers of ovarian cancer |
| CN104277102B (zh) * | 2014-06-27 | 2017-04-12 | 李光辉 | 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用 |
| GB201702091D0 (en) * | 2017-02-08 | 2017-03-22 | Medannex Ltd | Specific binding molecules |
| US20210292400A1 (en) | 2018-05-17 | 2021-09-23 | Yiping W. Han | Methods for treating, preventing and detecting the prognosis of colorectal cancer |
| US20210353721A1 (en) | 2018-08-07 | 2021-11-18 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1 |
| US20200171165A1 (en) | 2018-11-30 | 2020-06-04 | Proteogenomics Research Institute for Systems Medicine | Enhanced targeted delivery of therapeutic agents |
-
2018
- 2018-08-10 GB GBGB1813137.5A patent/GB201813137D0/en not_active Ceased
-
2019
- 2019-08-12 IL IL280421A patent/IL280421B2/en unknown
- 2019-08-12 KR KR1020217007105A patent/KR20210088523A/ko active Pending
- 2019-08-12 WO PCT/EP2019/071627 patent/WO2020030827A1/en not_active Ceased
- 2019-08-12 TW TW108128652A patent/TW202014437A/zh unknown
- 2019-08-12 EP EP19753344.1A patent/EP3833404A1/en active Pending
- 2019-08-12 MX MX2021001604A patent/MX2021001604A/es unknown
- 2019-08-12 CN CN201980064004.7A patent/CN112770786B/zh active Active
- 2019-08-12 JP JP2021506746A patent/JP7428696B2/ja active Active
- 2019-08-12 BR BR112021002435-2A patent/BR112021002435A2/pt unknown
- 2019-08-12 AU AU2019319092A patent/AU2019319092B2/en active Active
- 2019-08-12 US US17/266,883 patent/US11858982B2/en active Active
-
2024
- 2024-01-05 JP JP2024000815A patent/JP7728035B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021002435A2 (pt) | 2021-05-04 |
| US11858982B2 (en) | 2024-01-02 |
| CA3107674A1 (en) | 2020-02-13 |
| KR20210088523A (ko) | 2021-07-14 |
| EP3833404A1 (en) | 2021-06-16 |
| CN112770786B (zh) | 2023-10-27 |
| CN112770786A (zh) | 2021-05-07 |
| JP2024041851A (ja) | 2024-03-27 |
| TW202014437A (zh) | 2020-04-16 |
| WO2020030827A1 (en) | 2020-02-13 |
| US20210238269A1 (en) | 2021-08-05 |
| IL280421A (en) | 2021-03-25 |
| JP7428696B2 (ja) | 2024-02-06 |
| JP2021534121A (ja) | 2021-12-09 |
| GB201813137D0 (en) | 2018-09-26 |
| IL280421B2 (en) | 2024-06-01 |
| AU2019319092A1 (en) | 2021-03-18 |
| AU2019319092B2 (en) | 2026-04-02 |
| JP7728035B2 (ja) | 2025-08-22 |
| IL280421B1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009568A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| AR107442A1 (es) | Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer | |
| CL2019001198A1 (es) | Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple. | |
| ECSP19078429A (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| MX2020007527A (es) | Tratamiento de enfermedades oftalmologicas. | |
| CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| CO2019013669A2 (es) | Anticuerpos anti-garp-tgf-β | |
| UY37779A (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
| CO2017005240A2 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
| BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
| GT201700102A (es) | Conjugados de anticuerpo-fármaco | |
| MX2016009555A (es) | Proteinas de union y metodos para utilizarlas. | |
| DOP2016000283A (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
| MX2025003354A (es) | Anticuerpos que se unen a 5t4 | |
| CL2025000403A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| CU20170014A7 (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| CL2019002735A1 (es) | Anticuerpos que se unen a steap-1. | |
| MX2024013356A (es) | Anticuerpos anti alfa-sinucleina | |
| AR115288A1 (es) | Anticuerpos humanizados contra el psma | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
| AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. |